Nasdaq nmra.

Visualize o gráfico de Neumora Therapeutics, Inc. ao vivo para acompanhar o movimento do preço de suas ações. Encontre previsões de mercado, NMRA finanças e notícias do mercado.

Nasdaq nmra. Things To Know About Nasdaq nmra.

The latest price target for Structure Therapeutics ( NASDAQ: GPCR) was reported by JMP Securities on Monday, November 20, 2023. The analyst firm set a price target for 91.00 expecting GPCR to rise ...Nov 24, 2023 · Posted by Defense World Staff on Nov 24th, 2023. Shares of Neumora Therapeutics, Inc. ( NASDAQ:NMRA – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed ... View Our Latest Research Report on NMRA. Neumora Therapeutics Price Performance. NASDAQ:NMRA opened at $12.25 on Thursday. The stock has a fifty day simple moving average of $11.42.Neumora Therapeutics (NASDAQ:NMRA) shares are up over 15% this morning. 10 Top Losers Vivos Therapeutics (NASDAQ: VVOS ) stock is plummeting nearly 34% after a massive rally yesterday on FDA news .SpringWorks Therapeutics Inc (NASDAQ:SWTX)’s traded shares stood at 0.46 million during the last session, with the company’s beta value hitting 0.58. At the close of trading, the stock’s price was $20.71, to imply a decrease of -2.08% or -$0.44 in intraday trading. The SWTX share’s 52-week ...

A high-level overview of Neumora Therapeutics, Inc. (NMRA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …Neumora hopes to list its shares on Nasdaq under the symbol NMRA. JP Morgan, BofA Securities, Stifel, Guggenheim Securities, RBC Capital Markets and William Blair are serving a joint bookrunners.NASDAQ:NMRA Neumora Therapeutics (NMRA) Stock Price, News & Analysis $11.91 +0.22 (+1.88%) (As of 11/22/2023 ET) Compare Today's Range $11.76 $12.14 50-Day Range $9.64 $16.25 52-Week Range $9.35 $17.74 Volume 137,979 shs Average Volume 342,316 shs Market Capitalization $1.82 billion P/E Ratio N/A Dividend Yield N/A Price Target $22.67

Get the latest Neumora Therapeutics Inc (NMRA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

The latest price target for CymaBay Therapeutics ( NASDAQ: CBAY) was reported by Cantor Fitzgerald on Wednesday, November 8, 2023. The analyst firm set a price target for 24.00 expecting CBAY to ...Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, NMRA-CK1d, NMRA-NLRP3, and NMRA-GCase. NMRA-511 is an investigational antagonist of the vasopressin 1a receptor (V1aR). NMRA-266 is a positive allosteric modulator of the M4 muscarinic receptor (M4R) for the treatment of schizophrenia and other neuropsychiatric …Neumora Therapeutics, Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics, Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting.Dr. Lenz brings 20 years of neuroscience drug development expertise, with deep experience implementing successful clinical programs to support the development of novel medicines. WATERTOWN, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company …

Sep 21, 2023 · Shares of Neumora Therapeutics (NASDAQ: NMRA) were down more than 32% for the week as of Thursday's market close, according to data provided by S&P Global Market Intelligence.

Oct 10, 2023 · For Neumora Therapeutics Inc (NASDAQ:NMRA), William Blair initiated coverage, by setting the current rating at Outperform. The stock has a 52-week-high of $17.74 and a 52-week-low of $9.90.

NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. “The ...Successfully completed initial public offering: In September 2023, Neumora completed its initial public offering of its common stock and shares began trading on the Nasdaq Global Select Market under the ticker symbol “NMRA.” Since its inception, Neumora has raised over $850 million to further its mission to confront the global brain disease ...Neumora Therapeutics, Inc. Common Stock (NMRA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Neumora Therapeutics (NASDAQ:NMRA) shares are up over 15% this morning. 10 Top Losers Vivos Therapeutics (NASDAQ: VVOS ) stock is plummeting nearly 34% after a massive rally yesterday on FDA news .See the latest Neumora Therapeutics Inc stock price (NMRA:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Neumora Therapeutics Announces Initiation of Phase 3 Clinical Program for Navacaprant (NMRA-140) in Major Depressive Disorder WATERTOWN, Mass.--(BUSINESS WIRE)--Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the planned initiation of the …

WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced financial results for the third quarter ended September 30, 2023 and provided a general business update.Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) major shareholder Arch Venture Partners Xii, Llc bought 3,357 shares of the company’s stock in a transaction on Tuesday, November 14th.Veja a previsão de preço das ações da Neumora Therapeutics, Inc. para 1 ano, feita pelos analistas e compare-a com as mudanças de preço ao longo do tempo para desenvolver …WATERTOWN, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will participate in two investor conferences in November: Guggenheim Healthcare Talks 5th Annual INI …Explore Neumora Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 11 clinical trials, 46 news, and 3 literature, Disease Domain ...

View Your Watchlist. Stock analysis for Neumora Therapeutics Inc (NMRA:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and …NVDA. NVIDIA Corporation Common Stock. $449.995 +1.295 +0.29%. Neumora Therapeutics, Inc. Common Stock (NMRA) Advanced Charting - Nasdaq offers …

WATERTOWN, Mass., Oct. 30, 2023 -- Neumora Therapeutics, Inc. , a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will...THIRD QUARTER 2023 FINANCIAL RESULTS. The Company reported a net loss of $53.0 million for the third quarter of 2023, as compared to $29.3 million for the same period in 2022. Research and ...Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Neumora Therapeutics, Inc. Common Stock (NMRA) Pre-Market Stock Quotes - Nasdaq ...20 Nov 2023 ... NMRA:NSQNASDAQ. Neumora Therapeutics Inc. Actions. Add to watchlist; Add ... Its other product candidates include NMRA-511, NMRA-266, NMRA-NMDA, .../EIN News/ -- WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development ...NASDAQ: NMRA. $11.69-0.16 (-1.35%) Updated Nov 21, 2023. Open eToro Account. FAQ. How much does it cost to buy one Neumora Therapeutics share? As of . Nov 21, 2023, it costs $11.69 to buy one share of Neumora Therapeutics stock.Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs.

6 hari yang lalu ... (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced that the Company will ...

The latest price target for Neumora Therapeutics ( NASDAQ: NMRA) was reported by JP Morgan on Tuesday, October 10, 2023. The analyst firm set a price target for 21.00 expecting NMRA to rise to ...

Find the latest historical data for Nemaura Medical, Inc. Common Stock (NMRD) at Nasdaq.com.Current. -$0.75. 1 Month Ago. -$0.75. 3 Months Ago. N/A. Neumora Therapeutics Inc. analyst estimates, including NMRA earnings per share estimates and analyst recommendations.CGC. Canopy Growth Corporation Common Shares. $1.275 -0.065 -4.85%. Find the latest SEC Filings data for Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com.Nasdaq | NMRA U.S.: Nasdaq Neumora Therapeutics Inc. Watch list NEW Set a price target alert After Hours Last Updated: Oct 4, 2023 7:35 p.m. EDT Delayed quote $ 12.27 0.36 3.02% After Hours... The latest price target for CymaBay Therapeutics ( NASDAQ: CBAY) was reported by UBS on Tuesday, September 26, 2023. The analyst firm set a price target for 25.00 expecting CBAY to rise to within ...Nov 24, 2023 · Posted by Defense World Staff on Nov 24th, 2023. Shares of Neumora Therapeutics, Inc. ( NASDAQ:NMRA – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed ... Nov 1, 2023 · WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced ... Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the ...15 Sep 2023 ... Neumora Therapeutics, Inc. (Nasdaq: NMRA) visits the Nasdaq MarketSite in Times Square. Neumora Therapeutics, Inc. is a clinical-stage ...Stock Quote. NASDAQ GS: NMRA. $12.33. Dec 1, 2023 4:00 PM EST. Change. +0.08 (+0.65%). Volume. 232,481. Today's Open. $12.24. Previous Close. $12.25. Today's ...

Neumora Therapeutics, Inc. Common Stock (NMRA) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.Find the latest news headlines from Neumora Therapeutics, Inc. Common Stock (NMRA) at Nasdaq.com. Oct 10, 2023 · In addition, NMRA-266 (M4R PAM), another drug in development for the treatment of schizophrenia, is viewed as a de-risked asset due to the large market and low entry barriers for this disease. Instagram:https://instagram. pet insurance through costcobest home loan lenders in floridacf holdingscybersecurity+companies+stock+market+news Neumora Therapeutics Inc (NASDAQ: NMRA) gained 15.4% to $14.00 in pre-market trading. Neumora Therapeutics recently initiated a Phase 1 single ascending dose / multiple ascending dose study of ...Nov 27, 2023 · NMRA-266 is a highly selective positive allosteric modulator of the M4 muscarinic receptor that Neumora is developing as a treatment for schizophrenia and other neuropsychiatric disorders. mortgage companies in ctletax Neumora Therapeutics Inc. Common Stock stock price (NMRA) NASDAQ: NMRA. Buying or selling a stock that’s not traded in your local currency? Don’t let the currency conversion trip you up. Convert Neumora Therapeutics Inc. Common Stock stocks or shares into any currency with our handy tool, and you’ll always know what you’re getting. top stocks 2023 Veja o histórico completo das cotações para Neumora Therapeutics Inc, consulte informações sobre o preço de fechamento, de abertura, máximas, mínimas e as …NMRA Neumora Therapeutics, Inc. Stock Price & Overview. Follow 212 followers. $12.250.00 (0.00%)11:37 AM 12/01/23. NASDAQ | $USD | Realtime. Summary · Ratings ...